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Epidemiology 
Gestational diabetes mellitus (GDM) is defined 
as glucose intolerance with the onset or first 
detection during pregnancy.'" About 135,000 cases 
of GDM are diagnosed annually in the United 
States.2 Important risk factors include higher 
maternal age, family history of diabetes, and 
increased pregravid body mass index (BMI).3 The 
prevalence of GDM in low-risk populations ranges 
from 1.4% to 2.8%'·'; in high-risk populations, 
prevalence ranges from 3.3% to 6.1%.4 
Markedly elevated maternal glucose levels most 
often occur in women with pregestational diabetes. 
Pregnant women with pregestational diabetes are at 
higher risk for multiple complications affecting both 
the mother and the fetus than those women without 
diabetes. Current therapy improves outcomes for 
both mother and neonate.6 
The additional risk for adverse health outcomes 
· attributable to the milder degrees of maternal 
hyperglycemia associated with GDM and the 
magnitude of the benefit from treating that risk 
are less certain. No well-designed and conducted 
randomized controlled trial (RCT) of screening for 
1 
GDM has been completed, and thus the evidence 
for screening is indirect. 
National groups disagree about whether to 
recommend screening for GDM.2.7- 11 Despite no 
strong recommendations in favor of universal 
screening from the American College of 
Obstetricians and Gynecologists (ACOG), 94% 
of Fellows in office-based practices reported 
performing universal screening for GDM in 1996." 
Fellows performed this screening even though 
ACOG acknowledged the weakness in the evidence 
in both 1994" and 2000.' 
With continued controversy around the 
advisability of GDM screening, the RTI-Univ~rsity 
of North Carolina Evidence-based Practice Center 
(RTI-UNC EPC) conducted a systematic evidence 
review to assist the U.S. Preventive Services Task 
Force (USPSTF) in reconsidering its 1996 review, 
which found insufficient evidence to recommend 
screening. We restricted this review to screening 
for GDM after 24 weeks' gestation, thus excluding 
both women with known pregestational diabetes 
and those who are discovered by symptoms earlier 
in pregnancy. 
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Materials and Methods 
Sources 
Our review of the literature was guided by key 
questions and inclusion criteria we developed relevant 
to the issue of screening for GDM (Table 1). We 
required RCTs for direct evidence of the efficacy of 
treatment and the harms associated with treatment. 
We examined the critical literature from the 1996 
USPSTF review and searched MEDLINE and the 
Cochrane Library for reviews and relevant studies 
published in English between January I, 1994 and 
August 30, 2002. We supplemented this search by 
examining the reference lists of pertinent articles and 
by contacting experts. We also conducted focused 
searches ofMEDLINE from 1966 through 1994 to 
identify older articles of interest. 
Note: AU searches started with exploding "diabetes, gestational." 
Study Selection 
All searches began by exploding the term 
"diabetes, gestational" and then proceeded by 
adding further terms. We retrieved the full text 
of all articles we thought were potentially eligible. 
Two reviewers examined each article for eligibility. 
A single reviewer abstracted relevant data from 
the included articles; a second reviewer checked 
the abstractions. 
We abstracted all included articles, entered the 
data into evidence tables, graded the quality of all 
articles according to USPSTF criteria, 14 and 
resolved disagreements by discussion. We 
synthesized the evidence into a systematic evidence 
review; this was subjected to extensive external peer 
review and revised as appropriate. 15 The final 
systematic evidence review, including the evidence 
GDM indicates gestational diabetes mellitus; RCT, randomized clinical trial. 
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tables, is available on the Agency for Healthcare 
Research and Quality (AHRQ) Web site 
(www.preventiveservices.ahrq.gov). This article 
summarizes the evidence from that review. 
Results 
For the USPSTF to recommend screening for 
GDM, it must have either direct evidence from a 
randomized controlled rrial (RCT) of screening or 
indirect evidence that establishes a complete linkage 
between screening and improved health outcomes. 
We found no well-conducted RCT that provides 
direct evidence for the health benefits of screening 
for GDM. Given this, the USPSTF requires 
adequate evidence that: (!) untreated GDM causes 
substantial maternal and/or neonatal adverse health 
outcomes; (2) available screening tests accurately 
and efficiently detect GDM; and (3) available 
treatments improve health outcomes, with a 
magnitude that clearly justifies the harms and 
effort of screening and treatment. These issues 
will be examined in the sections that follow. 
What Adverse Health Outcomes 
Occur with Untreated GDM? 
Determining the existence and magnitude of a 
causal association between various degrees of GDM 
and adverse health outcomes is complex. We have 
only older studies of untreated GDM, at a time 
when obstetric practice differed from current 
practice, or more recent studies in which women 
received some treatment for GDM. Another 
problem with many studies is that they consider 
GDM as a dichotomous variable, yet we know that 
the risk for adverse health outcomes increases with 
the degree of hyperglycemia among women with 
GDM; the impact of hyperglycemia on adverse 
maternal and neonatal health outcomes is probably 
continuous.16-19 Few studies, however, stratify the 
risks ofGDM by severity of hyperglycemia. 
Offspring Health Outcomes 
BecaUse the literature is scant and mixed about 
whether untreated GDM, given optimal obstetric 
care today, is associated with increased perinatal 
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mortality, 19-27 the extent to which GDM is truly 
associated with perinatal mortality remains unclear. 
Macrosomia is an intermediate outcome of 
GDM. Three recent studies of untreated women 
with GDM"·"'"found that the percentage of 
infants with macrosomia weighing more than 4,000 
grams was berween about 17% and 29%; the 
percentage in the general population is about 
10%.26 Most infants with macrosomia are born to 
women without GDM28; maternal obesity is an 
important potential confounding factor associated 
with both GDM and (independently) with 
macrosomia. 
Important adverse neonatal health outcomes 
linked to macrosomia are brachial plexus injury and 
clavicular fracture. The best (although minimal) 
data on untreated women with GDM compared 
with the non-GDM population reveal no difference 
in the rate of infant brachial plexus injury or 
clavicular fracture. 22 Recent data suggest that women 
treated for GDM with more severe degrees of 
hyperglycemia may have a 2% absolute increase in 
having their infants develop a brachial plexus injury 
and a 6o/o increase in having their infants develop a 
clavicular fracture."-'' While these adverse health 
outcomes are of concern, the best studies show that 
80% to 90% of brachial plexus injuries resolve by 
one year of life,31)....33 and more than 95% of clavicular 
fractures heal within a few months without residual 
problems.34-39 
GDM may also be a risk factor for neonatal 
hypoglycemia. Studies among untreated" and 
treated women with GDM have found higher rates 
of neonatal hypoglycemia among untreated women 
with GDM. The magnitude of clinically important 
neonatal hypoglycemia is less clear. Also not clear is 
whether increased surveillance of infants whose 
mothers have GDM contributes to the increased 
finding of hypoglycemia in their infants. 
Likewise, the evidence is limited and unclear as 
to whether GDM is associated with preterm birth 
or neonatal hyperbilirubinemia, hypocalcemia, or 
polycythemia.1.2n.3s,40-44 Because of limited evidence 
and the increased surveillance given to infants of 
women with GDM, the magnitude of any 
associated adverse health effects is uncertain but is 
likely to be small. 
Some have suggested that the diagnosis of 
maternal GDM may have long-term implications 
for the offspring, such as an increased risk for 
impaired glucose tolerance, childhood obesity, and 
neuropsychological disturbances. No large 
observational study has followed a group of children 
whose mothers have GDM and a comparison group 
whose mothers do not have GDM long enough to 
demonstrate whether any of these hypotheses are 
correct.4>-48 
Maternal Health Outcomes 
The diagnosis of GDM can also increase adverse 
health outcomes for the mother during her 
pregnancy. Limited data since 1980 reveal total 
cesarean delivery rates of 22o/o49 to 30%21 fqr 
unrecognized or untreated women with GDM, 
compared with a rate of about 17% for women 
without GDM. Although the overall literature 
suggests an association between GDM and higher 
cesarean delivery rates/1•51l-54 some studies are limited 
by a lack of adjustment for maternal obesity and by 
the impact of the diagnosis of GDM on clinical 
decision-malting. 
Limited evidence is available on the rate of 
third- or fourth-degree lacerations in womeri 
with GDM. Some studies have suggested an 
increase/a but the only study that found a 
substantial percentage of women with untreated 
GDM who had such lacerations included only 
16 subjects." Another study found equally low 
rates among women with GDM and women 
without GDM." 
Overall, observational studies have shown 
mixed results and are inconclusive as to whether 
women with GDM have a higher risk for pre-
eclampsia than women without GDM.1·39•55- 57 
Recent data from untreated women with GDM22 
reveal a rate of pre-eclampsia {about 9o/o) that is 
similar to that for treated women and women 
without GDM.58-61 
Mothers identified as having gestational diabetes 
also have a higher risk for developing type 2 
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diabetes in the years after delivery.62 Studies 
investigating the rate of development of type 2 
diabetes after the onset of gestational diabetes have 
suffered from low participation rates, retrospective 
design, short follow-up, and variation in definition 
of both GDM and new diabetes. Although nearly 
all studies show that women who have GDM face 
some increased risk for devdoping diabetes, the 
degree of risk elevation they experience and the 
degree of glucose abnormality they develop are 
uncertain.' Further, the added benefit of early 
detection of diabetes in young women with few 
cardiovascular risk factors is uncertain. 63 
How Accurate and Reliable 
Are Screening Tests for GDM? 
Reference Diagnostic Test 
Before we can determine the accuracy of a 
screening test, we need a reference diagnostic test 
for comparison. Unfortunately, no universally 
agreed on reference test for the diagnosis of GDM 
exists. 
Three competing criteria for diagnostic glucose 
tolerance tests {GTT) are available (Table 2). 
Criteria from the World Health Organization 
(WHO)" label twice as many women with GDM 
as do criteria from the National Diabetes Data 
Group (NDDG).65 Criteria from the American 
Diabetes Association (ADA)66 give an intermediate 
prevalence. 2•67-69 
Abnormal values on any of the 3 tests are 
predictive of fetal macrosomia. 11'23'71l-72 This 
association is diminished or eliminated when 
adjustments are made for such potential confounders 
as pregravid weight, age, parity, and race. 
The reliability of any oral GTT is open to 
question. In 1 of the few studies on this issue, 
Harlass et al found that 23o/o of 64 unselected 
pregnant women who had had a positive screening 
test for GDM had inconsistent results between two 
100-grarn oral GTTs performed 1 week apart." 
Other studies have also raised concerns about the 
reproducibility of the oral GTT in nonpregnant 
groups.7+-76 
' 
'* Two or more criteria must be met or exceeded for a positive diagnosis. 
t One or more criteria must be met or exceeded for a positive diagnosis. 
Note: Double dash (-) indicates glucose levels not used for the test indicated. 
Screening Tests. The thresholds for the reference 
diagnostic tests do not dearly distinguish women 
at high risk from women at low risk for adverse 
maternal or neonatal health outcomes from GDM. 
Thus, we can evaluate screening tests only against 
imperfect standards. Most studies on GDM 
screening strategies compare the results of 1 test 
with the results of another test rather than 
examining how the test predicts adverse health 
outcomes. Some studies assess the association of 
the test with intermediate outcomes such as 
macrosomia rather than health outcomes such as 
brachial plexus injury. 
In the United States, the 50-gram, !-hour 
glucose challenge test {GCT) is most commonly 
used for screening {Table 2). Two groups have 
proposed different threshold criteria to define a 
positive screening test. If the GCT glucose value is 
above either 130 mg/dL77 or 140 mg/dL,65 then the 
patient is usually given the 100-gram GTT for 
diagnosis. Using the 130 mg/dl threshold, the GCT 
is positive for 20% to 25% of all pregnant women, 
including 90% of women with GDM. Using the 
140 mg/ dl threshold, the GCT is positive for 14% 
to 18% of all pregnant women, including about 
80% of women with GDM." 
In the general population, false-positive results 
for the GCT are common. Fewer than 1 in 5 
women with a positive GCT will meet criteria for 
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GDM on a full 100-gram GTT." The reliability of 
the GCT is also problematic." 
In many countries outside North America, 
clinicians use the "WHO screening approach: the 
75-gram 2-hour oral GTT as a single-step screening 
and diagnostic test. As noted above, this approach 
identifies at least twice as many women as having 
GDM as the two-step approach, although the 
evidence is sparse about whether the one-step test is 
more or less predictive of adverse health outcomes 
thaD; the two-step approach.68•69 
Because glucose intolerance increases during 
pregnancy, screening for GDM is most commonly 
conducted during the 24rh to 28th week of 
gestation. However, this timing is not based on any 
evidence that this is the optimal time to identify 
women who would benefit most from treatment. 
Determining the best time to screen involves 
examining the trade-off between the potential 
benefits of early screening (ie, finding fewer women 
at higher risk and treating them for a longer time) 
and the potential benefits of later screening {ie, 
finding a larger number of women at lower risk and 
treating them for a shorter time). 19 We found no 
study on this issue. 
One suggested approach to improve the 
efficiency of screening for GDM is to restrict 
screening to women at higher risk {"selective 
screening") rather than screening all women 
("universal screening"). In the most detailed study 
of selective screening strategies, Naylor et al 
developed a scoring system that excluded nearly 
35o/o of women from screening and actually 
detected more cases of G D M than universal 
screening. 61 
In summary, the evidence is unclear about the 
optimal screening and reference diagnostic test for 
screening for GDM. 
Does Treatment for GDM 
Improve Health Outcomes? 
Glycemic Control 
Three- factors are important in considering 
studies that evaluate the impact of tight glycemic 
control on health outcomes for women with GDM. 
The first is the degree of hyperglycemia in study 
participants. As the risk for at least some adverse 
health events increases with an increasing degree of 
hyperglycemia, the potential absolute risk reduction 
may be larger wirh higher glycemic levels. More 
than 70o/o of women diagnosed with GDM have 
mild hyperglycemia and are usually treared with 
diet alone.24•4L79 
The second important factor is the degree of 
separation of glycemic control between treatment 
groups. If intensive treatment does not produce a 
reasonable reduction in glycemic level compared 
with conventional treatment (or no treatment), 
the hypothesis of improved glycemic control leading 
to better health outcomes cannot be tested. 
The third factor in considering these studies is 
assessment of outcomes: which ones to assess and 
how to assess them. Most of these studies focused 
on intermediate outcomes such as fetal macrosomia 
or chemical findings such as neonatal 
hypoglycemia. Intermediate outcomes are useful 
only insofar as they predict important health 
outcomes that people care about. 14 In the case of 
fetal macrosomia, an intermediate outcome, only a 
small percentage of these cases lead to maternal or 
neonatal trauma. In the case of chemical findings 
(eg, glucose or bilirubin level), few studies reported 
the percentage of abnormalities that required 
1 
treatment; no study was clearly reassuring that 
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differences attributed to improved glycemic control 
were not associated instead with more intense 
surveillance of infants born to GDM mothers. 
Finally, because few of these studies masked the 
obstetricians, 80•81 interventions or outcomes that 
depend on clinician judgment (eg, cesarean 
delivery rates) could be biased by knowledge of 
GDM status.22 
Table 3 records clara from 9 RCTs examining rhe 
impact of therapy on a variety of outcomes.20•29•58-60,s0----83 
The 6-rst 4 RCTs are of women with mild 
hyperglycemia20•80·81•83 and the last 5 are of women 
with severe or very severe hyperglycemia.29•58-60·82 
Mild hyperglycemia. Few studies have examined 
the effectiveness of intensive compared with less 
intensive glycemic control among women with 
GDM who have mild hyperglycemia. An overview 
of 4 trials that included 612 women with mild 
hyperglycemia found no difference in adverse health 
outcomes between the women treated with a 
modified diet and the women receiving no therapy.84 
The Li et al RCT made a similar comparison and 
had similar findings." 
Three RCTs compared intensive with less 
intensive glycemic control (achieving some glycemic 
separation) among women with GDM who had 
varying degrees of hyperglycemia but a low mean 
entry fasting plasma glucose (FPG) or mean 
hemoglobin Ale (HbAlc)."·"·" Two studies found 
statistically significant improvements in 
intermediate outcomes for those women undergoing 
intensive glycemic control (eg, fewer large for 
gestational age [LGA] infants"; lower incidence of 
neonatal hypocalcemia"); no study found clear 
differences in health outcomes between glycemic 
control groups. 
Severe hyperglycemia. Four RCTs examined 
tight and less tight glycemic control among women 
with GDM at more severe hyperglycemic levels 
(Table 3)."·"·"'·" Of these trials, 3 achieved eirher 
small or no difference in glycemic control between 
groups and found no difference in major 
outcomes.29'5B.G0 One trial found a small absolute 
reduction in chemical abnormalities in the 
neonai:e58; another found a reduction in cesarean 
deliveries that was not explained by feral size.29 
¥---
' 
One study achieved a larger glycemic separation 
between groups {difference in mean glucose, 24 
mg/dL)." The infants of!ess intensively treated 
women had a higher mean birth weight plus higher 
rates of neonatal hypoglycemia and polycythemia. 
These differences were small and of uncertain 
clinical importance. 
Finally, de Veciana et a! compared tight with 
less tight control among women with very severe 
hyperglycemia, some of whom likely had frank 
diabetes {Table 3)." They also achieved the largest 
separation in glycemic control (HbAI c difference of 
1.6%) and found some of the larger reductions in 
fetal macrosomia and neonatal hypoglycemia. Given 
the study population, however, this trial may have 
little relevance for the great majority of women 
detected with GDM. 
A major issue in all of these trials is that they 
have too few participants to be able to detect small 
differences among treatment groups in such 
uncommon adverse health outcomes as perinatal 
mortality and brachial plexus injury. They have even 
less power to determine whether the health benefit 
is different for women with GDM who have severe 
hyperglycemia compared with those who have mild 
hyperglycemia. They provide insufficient evidence 
to confirm or refute the hypothesis that glycemic 
control improves health outcomes for women with 
GDM. 
Several observational studies without randomized 
controls have suggested improved intermediate or 
health outcomes with more intensive treatment of 
women with GDM.22.n.ss-91 The weakness in these 
studie·s is that women in the treatment groups differ 
from women in the control groups in multiple ways 
(some known and some unknown) other than 
glycemic control; most of the known factors are also 
associated with health outcomes. Thus. observed 
improvements in health outcomes may be 
attributable to factors other than glycemic control. 
In summary, although insulin therapy decreases 
the incidence of fetal macrosomia for those women 
with more severe degrees of hyperglycemia, the 
magnitude of any effect on maternal and neonatal 
health outcomes is not clear. The evidence is 
insufficient to determine the magnitude of health 
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benefit of tight glycemic control among the large 
number of women with GDM at milder degrees of 
hyperglycemia. 
Antepartum Surveillance 
Various approaches to antepartum surveillance 
might improve health outcomes among women with 
GDM. For non-stress testing {NST) or biophysical 
profile {BPP) to constitute a rationale for GDM 
screening, evidence would need to show that the use 
of these tests reduces stillbirth among women with 
GDM who have no other indication for these tests. 
This would require a large RCT, as most women 
with GDM have a low risk for having a stillbirth. 
No completed study of women with GDM has 
examined he:Mth outcomes among groups 
randomized to receive or not receive NST or BPP. 
Observational studies have found that using NSTs 
or BPPs in women with GDM is associated with 
either absent or very low rates of stillbirth.92- 95 
Without appropriate control groups we do not 
know whether the low rate of fetal death can be 
attributed to the additional procedures.'' NSTs or 
BPPs have high false-positive rates,"'" and they lead 
to interventions94 that may, on occasion. be 
unnecessary. 
Ultrasound assessment of abdominal 
circumference to allow improved targeting of insulin 
therapy in order to decrease fetal macrosomia and 
birth trauma has been studied. Three RCTs have 
enrolled women with hyperglycemia into insulin 
therapy triggered by ultrasound abdominal 
circumference. 29'83 '96 These studies have not found 
any important differences in health outcomes; 
all 3 lacked power to detect differences in health 
outcomes and in none were the obstetricians 
masked to the intervention group. 
What are the Harms and Costs 
of Screening and Treatment? 
Precise evidence on the harms and costs of 
screening for GDM and early treatment is lacking. 
Although not well documented, the potential for 
adverse psychological effects from screening is real; 
in the general population, more than 80% of all 
positive GCT screening tests are false positives.97 
j__ 
Note: AC indicates abdominal circumference; CPO, cephalopelvic disproportion; GDM, gestational diabetes meHitus; 
NDDG, National Diabetes Data Group; NR, not reported; NS, not statistically significant; stat sig, statistical significance; 
WHO, World Health Organization. 
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continued on page 10 
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Note: AC indicates abdominal circumference; CPO, cephalopelvic disproportion; GDM, gestational diabetes mellitus; 
NDDG, National Diabetes Data Group; NR, not reported; NS, not statistically significant; stat sig, statistical significance; 
WHO, World Health Organization. 
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Limited and mixed data suggest that labeling may 
negatively influence women's perceptions of their 
health during pregnancy97- 100 and that women 
diagnosed with GDM may have long-term changes 
in their perception of their own health.98'101 The 
long-term impact of these changes in perception of 
health is unclear. 
Identification of GDM may also needlessly 
increase the use ofNSTs or BPPs (triggering 
unnecessary interventions due to false positives) and 
rates of cesarean delivery (because of a lowered 
intervention threshold).22·7° Furthermore, additional 
tests and procedures increase the cost of screening 
programs. Because of the lack of evidence, the 
magnitude of other potential harms of aggressive 
glycemic-:lowering therapy, such as increased 
maternal starvation ketosis and infants who are 
small for gestational age, is difficult to quantify. 18•102 
As the effectiveness of screening in imprOving 
health outcomes is uncertain, so the cost-effectiveness 
cannot be calculated with any precision. We do not 
have good information about the differences in health 
care costs between screened and unscreened women. 
Discussion 
Maternal and neonatal morbidity increase with 
increasing levels of maternal hyperglycemia. 
Screening and intensive treatment for GDM aim to 
reduce this morbidity. Various screening strategies 
can detect women with different degrees of 
hyperglycemia, but the threshold at which health 
outcomes begin to deteriorate to a clinically 
important degree is uncertain. 
The magnitude of any benefit of intensive 
treatment at the various levels of hyperglycemia 
associated with GDM is also uncertain, but it is 
likely to be small among the many women with 
mild hyperglycemia. For women with GDM who 
have more severe hyperglycemia, intensive treatment 
is likely to reduce macrosomia. The extent to which · 
this translates into reductions in birth trauma is 
uncertain but probably substantially less than 
reductions in macrosomia. 
The evidence about the health outcomes of 
intensive treatment of women with GDM at various 
12 
levels of maternal hyperglycemia is indirect. It is also 
limited by a small number of srudies, small number 
of participants, lack of masking of obstetrical care, 
lack of control for important confounders, and lack 
of emphasis on health outcomes rather than 
intermediate outcomes. 
By making various assumptions, we can calculate 
the number needed to screen (NNS) to prevent 
various adverse health outcomes. Take, for example, 
the number of women needed to screen to prevent 
I case of brachial plexus injury (Table 4). Assume 
that 4% of pregnant women have GDM,' that 30% 
of them will have a high enough glycemic level to 
require insulin/9 and that, among these women, 
the macrosomia rate is reduced to the degree seen 
in the most positive srudy." The NNS to prevent 
one brachial plexus injury is about 8,900 (Case I, 
Table 4).32.33' 103 If we make more generous 
assumptions, the NNS becomes 3,300 (best case 
scenario, shown in Case 3 and footnote, Table 4). 
Assumptions including a lesser reduction in 
macrosomia, accounting for cesarean delivery rates, 
or using an outcome of permanent brachial plexus 
injury, would give much higher NNS estimates.' 
One potential benefit of detecting women with 
GDM is the knowledge that they have a higher risk 
for developing type 2 diabetes. The extent to which 
this information can lead to a health benefit for 
younger women with few cardiovascular risk factors, 
however, is uncertain. 63 
The evidence concerning the harms and costs 
of screening and intensive treatment is even more 
limited than the evidence about benefits, but several 
harms are of concern. Many women may suffer 
anxiety of uncertain duration because of a false-
positive screening test. Labeling women with GDM 
as having an increased risk for future GDM and 
type 2 diabetes may have psychological implications. 
Detection of GDM may increase the probability 
of cesarean delivery; multiple antenatal tests may 
increase the probability of a false-positive test leading 
to unnecessary procedures. Costs may be increased 
with little health benefit for many women, especially 
those many women with mild hyperglycemia. 
It is difficult to see how the issue of screening 
for GDM can be clarified without large RCTs with 
irifants (lr<>atme•~li1nc• tr,ea1:mE3rit)C: 
Difference: ca:se'' (l:vpided < 
Number needed toscreei1t'' 
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